Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novartis AG (NYSE:NVS)

80.11
Delayed Data
As of May 27
 -0.03 / -0.04%
Today’s Change
69.90
Today|||52-Week Range
106.84
-6.89%
Year-to-Date
This New Data Could Push Exelixis' Cabometyx Over $1 Billion in Peak Annual Sales
May 27 / MotleyFool.com - Paid Partner Content
Will These Game-Changing Cancer Treatments Hit the Market in 2016?
May 19 / MotleyFool.com - Paid Partner Content
Interested in Medivation? Take a Number!
May 27 / MotleyFool.com - Paid Partner Content
Novartis (NVS) to Stop Trial on Breast Cancer Drug Early
May 18 / Zacks.com - Paid Partner Content
PDL BioPharma Agrees to Equity Investment in Noden Pharma
May 25 / Zacks.com - Paid Partner Content
Better Buy: Regeneron Pharmaceuticals, Inc. vs. Ophthotech
May 17 / MotleyFool.com - Paid Partner Content
Novartis Filing for MabThera Biosimilar Accepted in the EU
May 24 / Zacks.com - Paid Partner Content
Novartis (NVS) Releases Positive Data on Ultibro Breezhaler
May 16 / Zacks.com - Paid Partner Content
The Best Buys in Biopharma Today
May 24 / MotleyFool.com - Paid Partner Content
Drug Stocks Reporting Earnings on May 17: AXON & FWP
May 16 / Zacks.com - Paid Partner Content
Novartis' Cardiovascular Drug Gets Positive Recommendation
May 23 / Zacks.com - Paid Partner Content